During the past decade, Swedish Cancer Institute-Eastside Oncology Hematology conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 23 clinical trials were completed, i.e. on average, 88.5% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 20 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Swedish Cancer Institute-Eastside Oncology Hematology" #1 sponsor was "National Cancer Institute (NCI)" with 16 trials, followed by "Alliance for Clinical Trials in Oncology" with 11 trials sponsored, "SWOG Cancer Research Network" with 8 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 2 trials sponsored and "GOG Foundation" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Swedish Cancer Institute-Eastside Oncology Hematology" #1 collaborator was "National Cancer Institute (NCI)" with 25 trials as a collaborator, "NRG Oncology" with 4 trials as a collaborator, "Canadian Cancer Trials Group" with 3 trials as a collaborator, "Agenus Inc." with 1 trials as a collaborator and "Astellas Pharma US, Inc." with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Swedish Cancer Institute-Eastside Oncology Hematology" are "Recurrent Squamous Cell Lung Carcinoma" (5 trials), "Stage IIIA Breast Cancer" (4 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (4 trials), "Recurrent Ovarian Carcinoma" (3 trials) and "Stage II Breast Cancer" (3 trials). Many other conditions were trialed in "Swedish Cancer Institute-Eastside Oncology Hematology" in a lesser frequency.

Most popular intervention types in "Swedish Cancer Institute-Eastside Oncology Hematology" are "Drug" (36 trials), "Other" (27 trials), "Biological" (15 trials), "Procedure" (11 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (19 trials), "Quality-of-Life Assessment" (9 trials), "Nivolumab" (6 trials), "Docetaxel" (5 trials) and "Carboplatin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Swedish Cancer Institute-Eastside Oncology Hematology" are 32 trials for "All" genders and 9 trials for "Female" genders.

Currently, there are NaN active trials in "Swedish Cancer Institute-Eastside Oncology Hematology". undefined are not yet recruiting, 3 are recruiting, 26 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Swedish Cancer Institute-Eastside Oncology Hematology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Swedish Cancer Institute-Eastside Oncology Hematology, 0 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".